Mechanisms of Alcohol-Nicotine Interactions: Alcoholics Versus Smokers

Authors

  • Toshio Narahashi,

    Corresponding author
    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • Bo Söderpalm,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • M. Ericson,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • P. Olausson,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • J. A. Engel,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • X. Zhang,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • A. Nordberg,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • William Marszalec,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • Gary L. Aistrup,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • L. G. Schmidt,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • U. Kalouti,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • M. Smolka,

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author
  • L. Hedlund

    1. Department of Molecular Pharmacology and Biological Chemistry (TN, WM, GLA), Northwestern University Medical School, Chicago, Illinois; the Department of Pharmacology, Institute of Physiology and Pharmacology (BS, ME, PO, JAE), Göteberg University, Göteberg, Sweden; the Division of Molecular Neuropharmacology (XZ, AN), Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden; the Department of Psychiatry (LGS, UK, MSm), Free University of Berlin, Germany; the Department of Psychiatry (MSo), University of Munich, Munich, Germany; Skellefteå Hospital (LH), Skellefteå, Sweden; and the Department of Pharmacology (GW), University of Umeå, Umeå, Sweden.
    Search for more papers by this author

Reprint requests: Toshio Narahashi, PhD, Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, 303 E. Chicago Avenue, Chicago, IL 60611-3008; Fax: 312-503-1700; E-mail: tna597@northwestern.edu

Abstract

This article represents the proceedings of a symposium at the 2000 ISBRA Meeting in Yokohama, Japan. The chairs were Toshio Narahashi and Bo Söderpalm. The presentations were (1) Nicotinic mechanisms and ethanol reinforcement: Behavioral and neurochemical studies, by Bo Söderpalm, M. Ericson, P. Olausson, and J. A. Engel; (2) Chronic nicotine and ethanol: Differential regulation in gene expression of nicotinic acetylcholine receptor subunits, by X. Zhang and A. Nordberg; (3) Nicotine-ethanol interactions at neuronal nicotinic acetylcholine receptors, by Toshio Narahashi, William Marszalec, and Gary L. Aistrup; (4) Relapse prevention in alcoholics by cigarette smoking? Treatment outcome in an observational study with acamprosate, by L.G. Schmidt, U. Kalouti, M. Smolka, and M. Soyka; and (5) Effect of nicotine on voluntary ethanol intake and development of alcohol dependence in male rats, by L. Hedlund and G. Wahlström.

Ancillary